GlassScriptPhysician profile
Chene T Smith
NPI 1417243247
$1,682.72
in general payments reported to CMS, 2019-2025
27 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $356 · 2020: $43.27 · 2021: $131 · 2022: $226 · 2023: $365 · 2024: $310 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $841 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $841.00 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $204.46 | 2019-2025 | Veozah |
| Pfizer INC. | $199.59 | 2019-2025 | |
| Abbvie INC. | $150.13 | 2022-2025 | Ubrelvy, Vraylar, Qulipta |
| Lilly USA, LLC | $148.03 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Dexcom, INC. | $118.80 | 2022-2024 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.98 | 2019-2025 | Jardiance |
| Glaxosmithkline, LLC. | $89.26 | 2019-2023 | Bexsero, Shingrix, Pediarix |
| Novo Nordisk INC | $77.56 | 2019-2023 | Ozempic, Rybelsus |
| Organon LLC | $73.45 | 2022-2025 | Nexplanon |
| Abbott Laboratories | $68.44 | 2019-2025 | Freestyle Libre 3, Infinity |
| Merck Sharp & Dohme LLC | $52.97 | 2019-2025 | Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $41.71 | 2024-2025 | Spravato |
| Amarin Pharma, INC. | $41.44 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $40.43 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $37.16 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $34.15 | 2020-2021 | |
| Biohaven Pharmaceuticals, INC. | $32.74 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.36 | 2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $18.22 | 2022 | |
| Sumitomo Pharma America, INC. | $17.70 | 2023 | Gemtesa |
| Amgen INC. | $16.35 | 2019 | |
| Idorsia Pharmaceuticals US INC | $15.42 | 2023 | Quviviq |
| Dynavax Technologies Corporation | $15.31 | 2025 | Heplisav-B |
| Exact Sciences Corporation | $14.44 | 2024 | Cologuard Collection Kit |
| Medtronic, INC. | $14.43 | 2022 | |
| Eisai INC. | $13.65 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.54 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chene Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.